Search clinical trials for: Ritlecitinib

Total 18 results

Pfizer

Recruiting

A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo (Tranquillo LTE)

Vitiligo

United States, Japan, Canada
Pfizer

Completed

A Target Occupancy Study With Ritlecitinib.

Healthy

United States
Icahn School of Medicine at Mount Sinai
Pfizer

Recruiting

Ritlecitinib in CTCL

Mycosis Fungoides | Sezary Syndrome | CTCL

United States
Emma Guttman
Pfizer

Recruiting

Ritlecitinib for Cicatricial Alopecia

Cicatricial Alopecia

United States
Pfizer

Completed

A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age

Alopecia Areata

United States
Icahn School of Medicine at Mount Sinai
Pfizer

Recruiting

Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy

Keloid

United States
Pfizer
In Expanded Access, treating physicians are the Sponsors

Available

Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)

Alopecia Areata
Pfizer

Completed

A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy Adults

Healthy Participants

United States
Pfizer

Recruiting

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo (Tranquillo)

Stable Nonsegmental Vitiligo | Active Nonsegmental Vitiligo

United States, Spain, Australia, Mexico, Canada, China, Japan, Italy, Turkey, Korea, Republic of, Germany, South Africa, Poland, United Kingdom, Bulgaria
Pfizer

Recruiting

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2 (Tranquillo 2)

Stable Nonsegmental Vitiligo | Active Nonsegmental Vitiligo

Japan, Canada, China, United States
Massachusetts General Hospital
Pfizer

Recruiting

Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission

Celiac Disease

United States
Pfizer

Not yet recruiting

A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without Food

Healthy Volunteers
Pfizer

Completed

A Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy Adults

Healthy Volunteers

Belgium
Pfizer

Completed

A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants

Healthy Volunteers | Pharmacokinetics | Adult

Belgium
Pfizer

Active, not recruiting

PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA (Allegro2a)

Alopecia Areata

United States, Australia, Canada, Poland
Pfizer

Completed

Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide

Healthy Volunteers

United States
National Institute of Diabetes and Digestive and...
Pfizer

Recruiting

Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

Diabetes Mellitus, Type 1

United States
Pfizer

Completed

Estimation of the Effect of Multiple Dose Ritlecitinib (PF-06651600) on the Pharmacokinetics of a Single Dose of Caffeine in Healthy Participants

Healthy Participants

United States

3

Subscribe